Our Network Tagrisso plus chemotherapy granted Priority Review in the US for patients with EGFR-mutated advanced lung cancer Tags: #Research #Oncology #Medical Oncology #Innovation #Clinical research #AstraZeneca #Regulation Decision based on FLAURA2 Phase III trial results which extended median progression-free survival by nearly 9 months versus standard of care.
